Hormone Therapy News

Menopause occurs at an average age of 51 years for most women in the United States, according to Mayo Clinic. However, about 5% of women younger than 45 years experience early menopause.

While menopause is a natural process of aging, some of its symptoms, such as hot flashes, may affect women’s well-being, according to Mayo Clinic.

Endocrine Today has compiled a list of the top five news reports posted in September. Healio.com/Endocrinology readers were interested in diet’s effect on thyroid function, the ‘Know Diabetes by Heart’ initiative and menopause’s interaction with sleep.

There is “insufficient evidence” to support the routine discontinuation of testosterone or spironolactone therapy in transgender patients who are undergoing scheduled surgical procedures, whereas inconsistent risk data regarding estrogen therapy suggests careful consideration about whether to stop before surgery, according to a systematic review published in JAMA Surgery.

Among postmenopausal women, current use of menopausal hormone therapy may double the risk for developing several hormone receptor-positive breast cancers, according to a case-control analysis published in PLOS ONE.

Among children with idiopathic short stature who do not test as growth hormone-deficient, the decision as to who receives coverage for GH therapy is unrelated to the degree of shortness or predicted adult height, according to a new analysis published in Endocrine Practice.

Only 30% of children who are prescribed growth hormone therapy consistently adhere to treatment, according to study findings from researchers in Israel.

A clinical trial funded by the National Institutes of Health will evaluate a male contraceptive gel for its ability to prevent pregnancy, according to a press release from the institution.

Despite negative findings from the physical function substudy of the Testosterone Trials, or T Trials, researchers conducting a secondary analysis of data from the entire T Trials cohort found greater evidence that walking ability and walking distance for older men with low testosterone levels may be improved by testosterone therapy.

The hormone kisspeptin could be used in treating conditions beyond reproductive disorders, including addressing metabolic dysfunction, particularly in men with high glucose and low testosterone levels, according to data presented at the Society for Endocrinology BES annual meeting.